Table 2 Interventions in the ScvO2-oriented group and lactate kinetics-oriented group during the treatment process
Lactate kinetics group | ScvO2 group | P value | |
|---|---|---|---|
n = 180 | n = 180 | ||
RBC volume at 24 h, ml | 144 ± 192 | 152 ± 193 | 0.705 |
Norepinephrine, % | |||
1st day | 46.1% (83/180) | 46.7% (84/180) | 0.916 |
2nd day | 38.9% (70/180) | 40.6% (73/180) | 0.747 |
3rd day | 27.2% (49/180) | 30.3% (54/180) | 0.560 |
Norepinephrine, μg/kg/h | |||
0 (0–4.46) | 0 (0–7.75) | 0.843 | |
0 (0–3.67) | 0 (0–7.19) | 0.1 | |
0 (0–0.57) | 0 (0–2.45) | 0.272 | |
Dobutamine, % | |||
1st day | 2.2% (4/180) | 3.9% (7/180) | 0.358 |
2nd day | 4.4% (8/180) | 3.3% (6/180) | 0.586 |
3rd day | 3.9% (7/180) | 3.3% (6/180) | 0.778 |
Dobutamine, μg/kg/h | |||
1st day | 0 (0–0) | 0 (0–0) | 0.325 |
2nd day | 0 (0–0) | 0 (0–0) | 0.263 |
3rd day | 0 (0–0) | 0 (0–0) | 0.618 |
CVVH | 26/154 | 36/144 | 0.163 |
Fluid volume, ml | |||
0–2 h | 563 (259–922) | 590 (288–960) | 0.539 |
2–4 h | 1535 (1271–1778) | 826 (631–1219) | <0.001 |
4–6 h | 1687 (1476–1929) | 1255 (1008–1537) | 0.358 |
6–12 h | 1688 (1173–1923) | 1277 (962–1588) | <0.001 |
12–24 h | 1510 (904–2087) | 1236 (740–1808) | 0.005 |
24–48 h | 465 (341–606) | 424 (279–552) | 0.071 |
48–72 h | 278 (159–410) | 284 (226–324) | 0.502 |